FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 158 filers reported holding FATE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $117 | +192.5% | 31,185 | +63.9% | 0.00% | – |
| Q3 2023 | $40 | -65.2% | 19,031 | -21.5% | 0.00% | -100.0% |
| Q2 2023 | $115 | -79.2% | 24,251 | -75.1% | 0.00% | -80.0% |
| Q1 2023 | $554 | -77.7% | 97,235 | -60.4% | 0.01% | -86.1% |
| Q4 2022 | $2,480 | -99.6% | 245,758 | +864.7% | 0.04% | +414.3% |
| Q3 2022 | $571,000 | -29.6% | 25,474 | +86.1% | 0.01% | -36.4% |
| Q3 2021 | $811,000 | -6.8% | 13,686 | +36.6% | 0.01% | +10.0% |
| Q2 2021 | $870,000 | -29.9% | 10,020 | -26.6% | 0.01% | -16.7% |
| Q4 2020 | $1,241,000 | +364.8% | 13,651 | +13.6% | 0.01% | -20.0% |
| Q1 2020 | $267,000 | – | 12,014 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $11,083,330 | 2.77% |
| Redmile Group, LLC | 13,169,057 | $43,194,507 | 2.61% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 497,360 | $1,631,341 | 2.06% |
| Boxer Capital, LLC | 8,215,910 | $26,948,185 | 1.42% |
| Deep Track Capital, LP | 5,572,607 | $18,278,151 | 0.55% |
| Vestal Point Capital, LP | 2,000,000 | $6,560,000 | 0.49% |
| Bruce & Co., Inc. | 300,000 | $984,000 | 0.32% |
| Octagon Capital Advisors LP | 520,800 | $1,708,224 | 0.27% |
| Integral Health Asset Management, LLC | 850,000 | $2,788,000 | 0.26% |
| Bellevue Group AG | 4,839,779 | $15,874,475 | 0.26% |